- ►jcojournal.org LR Silverman, EP Demakos, BL Peterson, AB … - Journal of Clinical Oncology, 2002 - jcojournal.org PATIENTS AND METHODS: A randomized controlled trial was undertaken in 191
patients with MDS to compare Aza C (75 mg/m 2 /d subcutaneously for 7 days every
28 days) with supportive care. MDS was defined by French-American-British ... Cited by 589 - Related articles - BL Direct - All 11 versions
- ►annals.org [PDF] V Santini, HM Kantarjian, JP Issa - Annals of internal medicine, 2001 - Am Coll Physicians Methylation of DNA is a biochemical modification that can influ- ence gene
expression and is involved in inactivating one of the two X chromosomes in
women. Evidence that has accumulated in the past 10 years suggests that ... Cited by 294 - Related articles - BL Direct - All 4 versions
J Goffin, E Eisenhauer - Annals of Oncology, 2002 - Eur Soc Med Oncology DNA methylation inhibitors have demonstrated the ability to inhibit
hypermethylation, restore suppressor gene expression and exert antitumor effects
in in vitro and in vivo laboratory models. Four inhibitors, which are ... Cited by 170 - Related articles - BL Direct - All 6 versions
- ►hematologylibrary.org AF List, J Vardiman, JPJ Issa, TM DeWitte - Hematology, 2004 - asheducationbook.hematologylibrary.org The development of new therapeutic strategies for myelodysplastic syndromes
(MDS) has gained new momentum fueled by improved characterization of the
disease's natural history and biology and by the recent US Food and Drug ... Cited by 113 - Related articles - All 6 versions
E Kaminskas, A Farrell, S Abraham, A Baird, … - Clinical Cancer Research, 2005 - AACR Results: In the controlled trial, the overall response rate was 15.7% in the
azacitidine treatment group; there were no responders in the observation group
(P < 0.0001). Response rates were similar in the two single arm studies. ... Cited by 101 - Related articles - All 4 versions
- ►hematologylibrary.org G Mufti, AF List, SD Gore, AYL Ho - Hematology, 2003 - asheducationbook.hematologylibrary.org The last decade has witnessed a multistep evolution in the understanding of the
natural history, clinical manifestations, and some of the molecular mechanisms
that underlie the ineffective hematopoiesis and leukemic transformation in ... Cited by 63 - Related articles - All 5 versions
- ►alphamedpress.org [PDF] E Kaminskas, AT Farrell, YC Wang, R … - The oncologist, 2005 - AlphaMed Press Page 1. FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza ™ )
for Injectable Suspension E DVARDAS K AMINSKAS , A NN ... Cited by 47 - Related articles - All 11 versions
W Hiddemann, T Büchner - Annals of Hematology, 1990 - Springer Summary. The strategy for treatment of relapsed or refractory acute myeloid
leukemia must primarily be based on the patient's age and clinical condition as
well as on the stage of the disease. Accordingly, the general decision ... Cited by 41 - Related articles - All 2 versions
